Product DevelopmentRelmada announced in-licensing of Trigone's NDV-01 for treating NMIBC, which is seen as a multi-billion opportunity.
Product PotentialNDV-01's novel sustained-release formulation could have blockbuster potential due to its ease of administration and increased efficacy.
Strategic DevelopmentThe sepranolone acquisition is seen as a first step in the right direction to maximize shareholder value, focusing on business development instead of selling the company or pursuing mergers and acquisitions.